Trelagliptin: A Literature Course on What the Published Studies Report

How this course is organised

This course summarises peer-reviewed literature on trelagliptin in six modules. Module 1 covers what the compound is and the settings in which it has been examined. Module 2 describes the mechanism as authors have proposed it. Module 3 walks study by study through reported outcomes. Module 4 collects published adverse-event reporting. Module 5 covers pharmacokinetics. Module 6 states regulatory facts. Each module ends with a short note on the limits of the evidence behind it, because a published finding in a mouse, a cell dish or a single national trial programme is not a general statement about people.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication or treatment decision. Nothing below describes how a compound should be used, and no outcome described in the literature is presented as an expected result.

Module 1: What trelagliptin is and how it has been studied

A 2015 review in Expert Opinion on Pharmacotherapy described trelagliptin as an orally administered dipeptidyl peptidase-4 (DPP-4) inhibitor investigated on a once-weekly schedule for type 2 diabetes mellitus (PMID 26523434). A separate 2015 report in Drugs documented the compound's first global approval, recording that trelagliptin was approved in Japan for type 2 diabetes mellitus and describing its development as an orally active, long-acting DPP-4 inhibitor (PMID 26115728). Both of those papers characterised the once-weekly dosing interval as the feature distinguishing trelagliptin from earlier daily agents in the same class (PMID 26523434, PMID 26115728).

Forms described in the literature

The salt form appears in the primary literature: a 2020 study in Biomedicine & Pharmacotherapy examined trelagliptin succinate in adipocytes and framed the work around insulin resistance in fat cells (PMID 32036216). Analytical work has also handled the molecule as a chiral compound: a 2019 paper in the Journal of Chromatographic Science developed an LC-MS/MS method to measure trelagliptin and its chiral bioconversion in beagle dog plasma (PMID 31844877).

Study settings represented in the verified literature

• Clinical review and approval reporting covering the type 2 diabetes development programme (PMID 26115728, PMID 26523434).
• Pooled clinical analysis: a 2022 meta-analysis in Diabetes & Metabolic Syndrome assessed safety and efficacy of once-weekly trelagliptin in type 2 diabetes (PMID 35344848).
• Post-approval safety review focused on Japanese patients with type 2 diabetes (PMID 28829213).
• Cell and animal experiments in chondrocytes, endothelial cells, adipocytes, vascular tissue, liver and lung (PMID 34666245, PMID 33049493, PMID 33421258, PMID 33751359).

Limits of the Module 1 evidence

The approval report and the once-weekly review are narrative summaries rather than original trials, so their descriptions of trelagliptin depend on the underlying programme they summarised (PMID 26115728, PMID 26523434). The clinical literature in this list is heavily weighted toward one country's patient population, and the laboratory papers used forms, concentrations and species that do not translate directly to human exposure.

Module 2: Mechanism as described in the literature

The proposed mechanism in the clinical literature is enzyme inhibition. Reviews described trelagliptin as a DPP-4 inhibitor, a class that acts by blocking the enzyme responsible for degrading incretin hormones, with the pharmacological rationale in type 2 diabetes framed around glucose-dependent insulin regulation (PMID 26523434, PMID 26115728).

Additional mechanisms proposed in preclinical papers

Several laboratory groups have proposed pathways beyond glycaemic control. A 2021 study in Molecular Immunology reported that trelagliptin improved interleukin-1β-impaired chondrocyte function and attributed the effect to the AMPK/SOX-9 pathway (PMID 34666245). A 2021 paper in Life Sciences reported that trelagliptin induced vasodilation and ascribed it to activation of voltage-gated potassium (Kv) channels and SERCA pumps (PMID 34358551). A 2020 study in International Immunopharmacology reported that trelagliptin inhibited interleukin-1β-induced endothelial inflammation and monocyte attachment (PMID 33049493). Researchers in a 2021 Inflammation paper described alleviation of lipopolysaccharide-induced inflammation and oxidative stress in a mouse acute lung injury model (PMID 33751359).

Limits of the Module 2 evidence

Mechanistic attributions in these papers were drawn from pathway markers measured in cells or isolated tissue, not from outcomes in patients (PMID 34666245, PMID 34358551). A pathway shown to move in a dish does not establish that the same pathway is engaged at human exposures, and none of the cited preclinical work was designed to test clinical endpoints.

Module 3: Reported outcomes by study

The table below lists the model, the endpoint area and what the authors reported. It is a map of the literature, not a summary of expected effects.

Limits of the Module 3 evidence

Six of the eight entries are preclinical. The two clinical entries summarise a trial programme conducted largely in one regulatory setting (PMID 35344848, PMID 26523434). Endpoints such as chondrocyte function, hepatic steatosis in mice and vascular tone in isolated tissue were exploratory and were not replicated in human trials in this evidence set.

Module 4: Trelagliptin Side Effects: What Studies Report

Adverse-event reporting for trelagliptin comes mainly from the clinical development programme and its post-approval summaries. A 2017 review in Expert Opinion on Drug Safety was dedicated to safety evaluation of trelagliptin in Japanese patients with type 2 diabetes mellitus and summarised adverse events recorded across that programme (PMID 28829213). The 2022 meta-analysis likewise examined safety alongside efficacy for once-weekly trelagliptin and compared adverse-event frequency against control treatment (PMID 35344848).

What the safety literature described

• The dedicated safety review reported that adverse events observed with trelagliptin in Japanese patients with type 2 diabetes were broadly consistent with those described for the DPP-4 inhibitor class (PMID 28829213).
• The meta-analysis reported that the overall incidence of adverse events with once-weekly trelagliptin did not differ substantially from comparator treatment across the pooled trials it analysed (PMID 35344848).
• The 2015 approval report and the once-weekly review both discussed tolerability data generated during the development programme that supported the regulatory submission (PMID 26115728, PMID 26523434).
• Hypoglycaemia risk in DPP-4 inhibitor programmes has been discussed in the context of combination therapy, and the safety review addressed adverse events in the Japanese treatment setting where such combinations are used (PMID 28829213).

Limits of the Module 4 evidence

Safety conclusions drawn in the cited reviews rest on trials of limited duration and on a single-country population (PMID 28829213, PMID 35344848). Rare events, long-term outcomes and effects in populations not enrolled — including people without type 2 diabetes — were not characterised by the papers in this list. No adverse-event frequency is stated here that the cited abstracts did not support.

Module 5: Pharmacokinetics where data exist

Human pharmacokinetic detail in this evidence set is limited to what the reviews summarised. The 2015 approval report described trelagliptin as a long-acting, orally active DPP-4 inhibitor, and the 2015 review framed the once-weekly interval as a pharmacokinetic property of the molecule rather than a formulation effect (PMID 26115728, PMID 26523434).

Animal pharmacokinetic work

A 2019 method paper measured trelagliptin in beagle dog plasma by LC-MS/MS and analysed chiral bioconversion of the compound alongside pharmacokinetic parameters (PMID 31844877). A 2025 study in Current Drug Metabolism examined the pharmacokinetics of trelagliptin in rats after exposure to acute and chronic high-altitude hypoxia, an environmental-physiology question rather than a therapeutic one (PMID 41116279).

Limits of the Module 5 evidence

The dog and rat studies described absorption and disposition in animals under specific laboratory conditions and were not human exposure studies (PMID 31844877, PMID 41116279). Species differences in metabolism mean these values are not interchangeable with human parameters, and the verified literature here contains no dedicated human pharmacokinetic trial report.

Module 6: Regulatory status, stated factually

The 2015 Drugs report documented trelagliptin's first global approval, in Japan, for type 2 diabetes mellitus, and the 2015 review discussed the compound in the context of that market authorisation (PMID 26115728, PMID 26523434).

• Approved product. The approval report identified an approved trelagliptin product indicated for type 2 diabetes mellitus in Japan (PMID 26115728).
• Other jurisdictions. Trelagliptin has not been approved as a prescription medicine by the United States Food and Drug Administration or the European Medicines Agency, and it therefore has no approved labelling in those regions.
• Research-use-only material. Chemical suppliers that list trelagliptin for laboratory work label it research use only, meaning the material is not intended for human or veterinary use and is not manufactured to pharmaceutical quality standards.
• Compounding. In the United States, compounding pharmacies operating under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act may compound only from bulk substances that meet statutory criteria; a compound without US approval and without listing on the relevant bulk-substance lists does not meet those criteria.

This section describes regulatory facts for educational purposes and is not legal advice.

Limits of the Module 6 evidence

Regulatory status changes over time and varies by country. The approval described in the 2015 report reflects the position at the time of publication, and readers checking current status should consult the relevant national regulator directly (PMID 26115728).

What the studies did not test

Reading the verified literature as a whole, several questions remain outside its scope:

1. Use outside type 2 diabetes. The clinical evidence concerned patients with type 2 diabetes mellitus (PMID 35344848, PMID 28829213); metabolically healthy people were not studied.
2. Whether preclinical findings translate. Reported effects on chondrocytes, endothelial cells, adipocytes, liver and lung were laboratory endpoints and were not followed by clinical trials in those indications (PMID 34666245, PMID 33421258).
3. Long-term cardiovascular or mortality outcomes. The cited papers assessed glycaemic and safety endpoints rather than long-horizon clinical outcomes (PMID 35344848).
4. Human pharmacokinetics under unusual conditions. The high-altitude hypoxia work was conducted in rats, not people (PMID 41116279).
5. Interactions and special populations. Pregnancy, paediatric use and detailed drug-interaction questions were not addressed by the abstracts in this evidence set.

Where a question is not answered by the cited papers, this course leaves it unanswered rather than filling the gap with inference. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any decision about a medication or health condition.

References

• Trelagliptin: First Global Approval (Drugs, 2015)
• First novel once-weekly DPP-4 inhibitor, trelagliptin, for the treatment of type 2 diabetes mellitus (Expert Opinion on Pharmacotherapy, 2015)
• Safety and efficacy of once weekly dipeptidyl-peptidase-4 inhibitor trelagliptin in type-2 diabetes: A meta-analysis (Diabetes & Metabolic Syndrome, 2022)
• Safety evaluation of trelagliptin in the treatment of Japanese type 2 diabetes mellitus patients (Expert Opinion on Drug Safety, 2017)
• Trelagliptin ameliorates IL-1β-impaired chondrocyte function via the AMPK/SOX-9 pathway (Molecular Immunology, 2021)
• The anti-diabetic drug trelagliptin induces vasodilation via activation of Kv channels and SERCA pumps (Life Sciences, 2021)
• Trelagliptin Alleviates Lipopolysaccharide (LPS)-Induced Inflammation and Oxidative Stress in Acute Lung Injury Mice (Inflammation, 2021)
• The dipeptidyl peptidase (DPP)-4 inhibitor trelagliptin inhibits IL-1β-induced endothelial inflammation and monocytes attachment (International Immunopharmacology, 2020)
• The Chiral Bioconversion and Pharmacokinetic Analysis of Trelagliptin in Beagle Dog Plasma by LC-MS/MS (Journal of Chromatographic Science, 2019)
• The protective effects of trelagliptin on high-fat diet-induced nonalcoholic fatty liver disease in mice (Journal of Biochemical and Molecular Toxicology, 2021)
• Trelagliptin succinate: DPP-4 inhibitor to improve insulin resistance in adipocytes (Biomedicine & Pharmacotherapy, 2020)
• Pharmacokinetics of Trelagliptin in Rats after Exposure to Acute and Chronic High Altitude Hypoxia (Current Drug Metabolism, 2025)